Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
Cureus ; 15(9): e45950, 2023 Sep.
Article in English | MEDLINE | ID: mdl-37885508

ABSTRACT

Takayasu arteritis (TA) is a heterogeneous disease whose presentation and progression have not yet been well described. An elderly female was diagnosed with TA after presenting with bilateral arm claudication, elevated ESR, and bilateral subclavian arterial stenosis. In the first two years after diagnosis, she was diagnosed with monoclonal gammopathy of undetermined significance and alpha thalassemia minor. For the next two years, she presented with a non-ST elevation myocardial infarction, three oozing Dieulafoy lesions, and eosinophilic esophagitis. As we observed, TA can have an unusual and unpredictable progression. Therefore, a multidisciplinary approach and clinical surveillance are paramount.

2.
Case Rep Med ; 2021: 5523562, 2021.
Article in English | MEDLINE | ID: mdl-34497649

ABSTRACT

Clozapine is an atypical antipsychotic used in refractory schizophrenia and depression. Its use is often complicated by its vast side-effect profile including cardiovascular reactions, agranulocytosis, and seizures. Specifically, the cardiac complications of clozapine have been shown to predominantly cause myocarditis and pericarditis. In this case report, the case of a 58-year-old male being treated for treatment-resistant depression and schizophrenia who suffers from tachycardia is presented. He is treated empirically for orthostatic hypotension with IV fluids without much success. Further imaging and echocardiography demonstrated a pericardial effusion, a rare reaction (≤1 : 10000) that has only been documented in a handful of case reports. This anecdotal evidence highlights the significance of polyserositis/pericardial effusion in the context of clozapine-induced orthostatic hypotension resistant to rehydration. When starting a patient on clozapine, it is important to consider further workup and monitoring with laboratory baseline biomarkers and cardiac evaluation with symptomatic individuals. Upon immediate cessation of clozapine, the pericardial effusion should spontaneously resolve without complication and should not be rechallenged.

3.
BMJ Case Rep ; 20142014 May 19.
Article in English | MEDLINE | ID: mdl-24842353

ABSTRACT

Tyrosine kinase inhibitors are novel antineoplastic drugs that make use of the molecular abnormalities that have been discovered in certain types of tumours. These agents are associated with important dermatological side effects. This case report discusses an atypical presentation of the hand-foot syndrome in one patient treated with sorafenib. A 78-year-old man, recently started on sorafenib for the treatment of hepatocarcinoma with lung metastasis, presented to the emergency room with painful blistering lesions on the palms, soles and scrotum for 1 week. A punch biopsy was performed and sorafenib was withheld. Direct immunofluorescence study was negative for an autoimmune blistering disorder and histopathology stains did not show any microorganisms. A diagnosis of hand-foot syndrome was made. After 2 weeks, the patient showed marked improvement and the plan was to restart sorafenib at a lower dosage.


Subject(s)
Blister/chemically induced , Drug Eruptions/etiology , Foot Dermatoses/etiology , Niacinamide/analogs & derivatives , Phenylurea Compounds/adverse effects , Protein Kinase Inhibitors/adverse effects , Administration, Oral , Administration, Topical , Adrenal Cortex Hormones/administration & dosage , Aged , Blister/physiopathology , Carcinoma, Hepatocellular/drug therapy , Carcinoma, Hepatocellular/secondary , Drug Eruptions/physiopathology , Foot Dermatoses/physiopathology , Hand Dermatoses/chemically induced , Hand Dermatoses/physiopathology , Humans , Liver Neoplasms/drug therapy , Liver Neoplasms/pathology , Lung Neoplasms/drug therapy , Lung Neoplasms/secondary , Male , Niacinamide/adverse effects , Niacinamide/therapeutic use , Phenylurea Compounds/therapeutic use , Prognosis , Protein Kinase Inhibitors/therapeutic use , Scrotum , Severity of Illness Index , Sorafenib , Syndrome , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL
...